NEW YORK (GenomeWeb) – Abbott has inked deals with Celgene and Agios Pharmaceuticals to develop and commercialize PCR-based companion diagnostic tests that will identify isocitrate dehydrogenase (IDH) mutations in patients with acute myeloid leukemia.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.